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Interpreting research findings to guide treatment in practice
Tony Kendrick,1 Kelsey Hegarty,2 Paul Glasziou3
When applying research findings to
individual patients, practitioners can use the
PICO approach, which considers
characteristics of the patient or population,
intervention, comparator or context, and
outcome. Patient centred practitioners
should however identify the outcomes
which are important to individual patients
Trials are important but not sufficient for good clinical
decision making. Recommendations derived from
trials in groups of patients must be interpreted and
adapted by clinicians to the context of each individual
patient seen in practice.1 The spectrum of patients in
primary care is often very different from that in
secondary care and clinical trials. In general, practi-
tioners have two options: to consider how the
treatment’s benefits and harms will differ given the
severity, risk, and context of the individual patient, or
to use a “try it and see” approach (or,more formally, do
an “n of 1” trial). There is a range between these
options. Take the example of the case of depression
described in box 1.
Do depression guidelines help clinicians for this
individual case?
Current guidelines in Australia and New Zealand,
Canada, theUnitedKingdom, and theUnited States all
recommend similar treatments formajor depressionor
dysthymia (chronic mild depression) diagnosed
according to psychiatric classification systems (DSM-
IV or ICD-10).3-6 The twomanagement strategies they
most strongly support—antidepressants or cognitive
behavioural therapy (CBT)—have been evaluated
mainly among patients with major depression, mostly
in secondary or tertiary care settings.
Guidelines from NICE (the UK’s National Institute
for Health and Clinical Excellence) on antidepressant
treatment were based on a review that included 31
outpatient studies, three inpatient studies, andonly one
study from primary care.5 A subsequent systematic
reviewofprimarycarebased trials identified12 studies,
but most were small, commercially funded studies of
short duration and lowmethodological quality.7 8 Little
of the evidence about antidepressants is derived from
the typeofdepression seenmorecommonly inprimary
care,which is less severe thanmajordepressionand less
chronic than dysthymia. The most recent systematic
review of 35 published and unpublished trials from the
US Food and Drug Administration database included
only one trial in mild depression.9 Most trials have
excluded patients with considerable alcohol use or
comorbid physical conditions such as epilepsy that
could be adversely affected by antidepressants.10 The
treatment recommendations also fail to acknowledge
patients’ reluctance to take drugs and do not address
whether treatment works in the face of the social
adversityusually associatedwithdepression inprimary
care.11 12 More primary care based evidence exists to
support the use of counselling and cognitive beha-
vioural therapy,butonly forpatientswithdepressionof
a severity comparable to that of patients seen in
outpatient settings.13 14 For milder depression, the
guidelines mention the need to deal with social issues
and suggest patient education and self help strategies
based on principles of cognitive behavioural therapy,
Box 1 A patient with depression after marriage break up
A54yearoldmanpresentswith lowmoodafter separating
from his wife of 30 years. He is usually seen only twice a
year for reviewofhisepilepsydrugs, tends toplaydownhis
symptoms, and has no history of depression. He has been
unable to work for three weeks owing to reduced sleep,
energy, appetite, and lack of motivation. He is now living
alone in bed and breakfast accommodation and drinking
more alcohol, is having thoughts about suicide but has no
specific plans, and is not keen on antidepressants as he
believes they can be addictive. He scores 14 out of 27 on
the patient health questionnaire (PHQ-9), indicating mild
major depression.2 The GP discusses the pros and cons of
antidepressants, explores with the patient what strategies
he will use to address his situation, and certifies him
unable to work.
Aweek later,withhiswifenowtakingsteps todivorcehim,
he says he feels more down, and his PHQ-9 score is 18,
indicating moderate to severe major depression.
However, a friend has given him a room to stay in for a few
months; he has stopped drinking and now wants to try
antidepressants so he can get back to work.
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but the evidence for these interventions inprimary care
settings is limited.15
How might benefits and harms in clinical settings differ
from the research setting?
The figure provides a model to help think through the
issues of transferability and application of research
findings.1 In general, benefits will be higher in patients
with higher risk ormore severe illnesses. 1 9 The top line
shows the likely increase in benefit if the trial’s results
apply across the spectrum of risk or severity of the
condition. However, the relative effectiveness in
primary care may be less (lower line) for several
reasons—for example, because compared with every-
day practice, trials may use tighter diagnostic rules,
ensure higher levels of adherence to treatment, and fail
to follow up patients with a poorer outcome. As trials
often include a higher proportion of patients with
severe disease or at high risk, the reported net benefit
will be higher than in actual practice. This difference
will be even greater for primary care, where most
patients are likely to be at lower severity or risk.
However, a primary care patient who is similar to the
patients in the trial (the patient represented by the open
circle near the right in figure 1), should receive similar
benefit. Every clinician must answer the following
question: “For this patient does the severity or risk
reach the threshold where benefits outweigh harms
such as adverse effects and inconvenience?”
How should we estimate an individual patient’s likely
response to treatment?
Let us apply this approach to the depressed man in
box 1. Box 2 shows some of the factors to be
considered.16
In the UK the commonest immediate decision is
whether to prescribe an antidepressant, as cognitive
behavioural therapy is usually not available or has a
waiting list of several months. Since 2006, UK general
practitioners have been remunerated for using ques-
tionnaire measures of the severity of depression at the
outset of treatment, and the patient in box 1 scores just
above the threshold for major depression, suggesting
that antidepressants may be of benefit. However, the
doctor is aware that the positive predictive value of the
PHQ-9 for major depression is likely to be lower in
primary care than in secondary care due to the
relatively lower prevalence, and therefore the patient
may be a false positive case given his borderline score.
So the doctor does not prescribe antidepressants on
the basis of one marginally raised PHQ-9 score alone,
especially as the patient is not keen on taking them and
may be at risk of taking an overdose while acutely
distressed. Also antidepressants may lower the thresh-
old for epileptic convulsions. Instead the doctor
discusses with the patient the possible benefits and
side effects of antidepressants and arranges a review a
week later. The patient clearly needs follow-up, as he
tends to play down his symptoms, his functioning is
impaired, and—being an older, socially isolated male
with increased alcohol use—he is at increased risk of
suicide (although the doctor is aware that having all
these epidemiological risk factors is still a poor
predictor of actual suicide in any individual case).
At review the symptom severity score is higher,
indicating moderate to severe major depression. The
patient’s preference is now forantidepressants andhe is
less socially isolated, reducing the suicide risk. He is
now seen to be more like the patients included in trials
of antidepressants, and the balance of the decision tips
towards prescribing antidepressants. Caution is
needed however, given the possible adverse effect of
precipitating epileptic convulsions, with possible risks
to the patient’s driving licence and job, and it would be
reasonable to monitor the patient for longer, as his
social situation is in flux and changes over the next few
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Box 2 Factors to take into account in the individual case: the PICO approach16
Population—is the individual in front of you sufficiently similar to trial participants to be
likely to gain a similar relative benefit from treatment?
Is the patient diagnostically similar to patients in the trials? (Take into account the
limitations of secondary care diagnostic tests in the primary care setting)
Are the likely benefits and harms of treatment similar to those in the trials?
Intervention—how similar will the treatment be to that given in the trial?
Is sufficiently similar treatment available and accessible?
Will the patient adhere to it? (Have you explored the patient’s preferences?)
Context or comparator treatments— are there specific contextual issues for the individual
that are very different from the trial context and likely to influence the outcome for the
patient? What are the alternatives to the specific treatment being considered?
Does the patient have complications or co-morbid conditions which would affect the likely
benefits or harms?
Are there other prognostic factors which were not measured in the trials?
Is the patient likely to improve without treatment anyway?
Outcome—are the outcomes assessed in the trials, the same outcomes that are important
for this individual?
Have you established what is important to the patient?
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weeks may lead to considerable improvement.12
Prescribing can also be viewed negatively as a way of
“disposing” of the patient which medicalises under-
standable reactions to life’s difficulties, precludes
further in depth exploration of the person’s circum-
stances and own resources, and risks subsequent
adverse effects on the doctor-patient relationship.12 17
If the doctor does decide to prescribe antidepressants,
further discussion of the benefits of treatment,
prompted at regular follow-up encounters, is likely to
maximise the patient’s adherence to treatment.18
Encouraging questions, in a collaborative patient
centred relationship, is likely to lead to a better
outcome.19 Case management programmes have
been shown repeatedly to ensure the best outcomes
through suchengagement, but at present arenotwidely
available in primary care.20
The decision to apply research findings in practice
depends not just on the setting but on the risk, severity,
and context of the individual patient; the relationship
between doctor and patient, and the availability of
other resources to offer the patient as an alternative to
medication. The transferability and applicability of
secondary care evidence to primary care will vary
betweendisorders. For depression, the spectrumseems
quite different,making it difficult inmany cases to base
treatment decisions on evidence from trials. In many
cases, the default position should be not to treat, at least
initially, to avoid doing the patient harm, while
watching for the development of more severe depres-
sion. The same principles could be applied to other
commonconditions suchasmigraine, for example.Yet
in other conditions, the trial evidence can be applied
directly. For example, for the use of statins after
myocardial infarction the trial participants may have
been recruited in hospitals but are actually the set of
patients discharged to primary care for treatment, and
hence the guideline recommendations are much more
readily applicable.
N of 1 trials
For some conditions we can use the “n of 1 trial”
approach to check whether a particular treatment
works for a particular individual. For example, to
determine whether a non-steroidal anti-inflammatory
drug (NSAID) is better than paracetamol for arthritis,
we could ask a patient to alternate paracetamol and the
NSAID for a few days at a time over some weeks and
record pain daily to measure the relative benefit. This
would be most rigorous if similar preparations of each
medication were used and the patient was unaware
which was which—this would reduce the placebo
effect, which would tend otherwise to favour the
NSAID.16 Other examples of this “try it and see”
approach, which will be familiar to general practi-
tioners, include trying different creams on different
parts of an apparently eczematous rash, or different eye
drops in each eye for dry eyes.
Unfortunately, thenof 1 approachdoesn’t workwell
in the case of depression, as antidepressants take some
weeks to work, and a wash-out period is often needed
between different types. Patients who have tried
various treatments in the past can obviously tell us
which seemed to work best for them. Otherwise we
have to consider howwell the evidence from groups of
patients might apply in the individual case.
How can the evidence base be improved to be useful in
individual cases?
To better inform treatment decisions we need more
studies of the courseof conditionswithout treatment, to
identify predictors of who needs active treatment. We
also need trials that include patientswithmild aswell as
more severe conditions, and with comorbidities that
might affect the relative benefits and harms of
treatments. Patients’ preferences need to be taken
into account in research designs, and outcomes
important to patients need to be measured.
Studies will often need to be large, so that they have
sufficient power for subgroup analyses to measure the
effects of important predictors of response, including
age, sex, and ethnic minority differences and variable
adherence to treatment. Such studies would be better
carried out in primary care, and clinicians should be
prepared to take part in studies that will directly inform
their practice, facilitating the negotiation of a truly
informed decision between clinician and patient.
However, some extrapolation from trial populations,
whether they are from primary or secondary care, will
always be necessary, as research studies can never
include every possible type of patient presenting in
practice.
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UNCERTAINTIES PAGE
What is the optimal management of partial epilepsy
uncontrolled by a first choice anticonvulsant?
David W Chadwick,1 Gus A Baker,1 Ann Jacoby,1 Anthony G Marson,1 Phil E Smith2
Up to 70% of people who are treated with a single
anticonvulsant will enter remission within a short time
of being diagnosedwith epilepsy.1 Optimal first choice
treatments have been identified in some comparative
randomised controlled trials and guidelines from the
National Institute forHealth andClinicalExcellence.2 3
Lamotrigine or carbamazepine are usually the pre-
ferred initial treatment of seizures with localised onset
in the brain, whereas valproate is preferred for
generalised epilepsy syndromes.4 5
However, despite optimal doses of a first line
anticonvulsant, many patients with localised onset
seizures (10-15/100 000 each year worldwide) do not
enter remission and continue to have seizures of
varying severity and frequency, which are associated
with considerable psychosocial distress.6 7 The evi-
dence base to support management of these patients is
minimal,2 and it is uncertain which of the following
available options is optimal:
 Continue with the existing first line treatment as
monotherapy.
 Switch to an alternative second line drug as
monotherapy.
 Add a second drug to the existing first line
treatment.
What is the evidence of uncertainty?
A single small randomised study has compared the
options of switching anticonvulsants or adding a
second drug.8 No differences were detected, but the
study was small and lacked sufficient power to detect
clinically important differences.
A large number of placebo controlled regulatory
studies in patients with refractory localised onset
seizures have indicated some short term reduction in
the frequency of seizures after adding a second
anticonvulsant to the existing treatment.9 This poten-
tial benefit is, however, accompanied by an increased
incidence of adverse events. The longer term effect of
this risk-benefit ratio onpatient perceivedquality of life
is uncertain. Studies in patients with less severe
epilepsy (those in seizure remission on drug treatment
and those with few or infrequent seizures at diagnosis)
show that the benefits from improved seizure control
are equally balanced by worse quality of life as a result
of taking anticonvulsants.10 11
We also have no evidence onwhich second line drug
is optimal. Over the past two decades, many newer
anticonvulsants have been licensed for add-on treat-
ment for localised onset seizures. Consequently,
patients with refractory seizures have had their
treatment regimen changed frequently, with uncertain
benefits.
Is ongoing research likely to provide relevant evidence?
There are some existing and planned industry spon-
sored studies comparing the addition of different
second linedrugs.However, these are of short duration
and are not suited to looking at important longer term
patient based outcomes that are crucial to guide
treatment choices in a chronic disorder such as
epilepsy.
What should we do in the light of the uncertainty?
In patients with continuing localised onset seizures
despite optimal first line therapy, consider adding a
second anticonvulsant. A consensus evidence-free
view is that when drugs are combined they should
have differing primary mechanisms of action and no
pharmacokinetic interaction.12 Most first line
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anticonvulsants (carbamazepine, lamotrigine, pheny-
toin, oxcarbazepine) act on sodium channels. Of the
commonly used first line add-on anticonvulsants, our
currentpreferredoptions include clobazam (whichacts
at GABA (γ-aminobutyric acid) receptors) or levetir-
acetam (which binds synaptic vesicle protein 2A).9 No
evidence is available to support our choice of add-on—
topiramate, pregabalin, and zonisamide are all reason-
able alternatives.
A randomisedcontrolled trial is urgentlyneeded that
compares adding placebo with adding one or two
second line agents to existing optimally dosed treat-
ment with carbamazepine, lamotrigine, phenytoin, or
oxcarbazepine in patients with continuing localised
onset seizures. Such a trial should evaluate longer term
clinical, patient based, and health economic outcomes.
Input from patients and carers is essential to help
understand the balance between the effects of
improved seizure control and the additional burden
of drug treatment. In the meantime, patients should be
offered the addition of a second line anticonvulsant,
such as clobazam or levetiracetam, with appropriate
counselling about risks and benefits and the opportu-
nity to reviewoutcomesover the short tomediumterm.
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LESSON OF THE WEEK
Acute phosphate nephropathy after sodium phosphate
preparations
Andrew Connor,1 Lucy Sykes,1 Ian S D Roberts,2 Charles E Weston1
Predisposed individuals may develop
chronic kidney disease after administration
of sodium phosphate purgative before
colonoscopy
Oral sodiumphosphate preparations are used as bowel
purgatives before colonoscopy. Subsequent renal
impairment is increasingly being reported.1 We
describe a case of acute phosphate nephropathy with
persistent renal impairment after administration of
sodium phosphate.
Case report
A 76 year old woman was admitted with rectal
bleeding. Her past medical history included
hypertension—treated with nifedipine—and long
standing use of tobacco. Physical examination was
unremarkable.
Laboratory results were normal—haemoglobin
106 g/l, white cell count 7.2×109/l, platelets 357×109/l,
sodium 132 mmol/l, potassium 4.3 mmol/l, urea
6.2 mmol/l, and creatinine 98 µmol/l.
She underwent flexible sigmoidoscopy after being
given a sodium phosphate enema (Fleet Ready-to-
RECOMMENDATION FOR FURTHER RESEARCH
Population: patients with localised onset seizures without remission after adequate
sequential treatment with two or more antiepileptic drugs
Intervention and comparison: add-on treatment with one antiepileptic drug compared with
add-on treatmentwithanalternativeantiepilepticdrugcomparedwithcontinuedoptimised
treatment with the existing single drug
Outcome: frequency of seizures
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use; De Witt) the night before (day 1). Colonoscopy
was performed on day 4 after she took two sachets of
oral sodium phosphate solution (Fleet Phospho-
soda; DeWitt). Histological findings were consistent
with chronic active ulcerative colitis. She was
discharged and prescribed mesalazine.
On day 6 she presented with acute renal failure
(creatinine 541 µmol/l). She received intravenous
fluids and mesalazine was replaced by prednisolone
enemas. A renal consultation was obtained.
Urinalysis was unremarkable. She was normocal-
caemic (2.4 mmol/l) but mildly hyperphosphatae-
mic (1.54 mmol/l). Results of a screen for
glomerulonephritis and renal tract ultrasonography
were normal. Interstitial nephritis secondary to
mesalazine was considered and she underwent
renal biopsy.
Twenty seven glomeruli were identified; one was
globally sclerosed and the others were normal. The
striking feature was widespread tubular calcification
(figure). Von Kossa stain accentuated the phosphate
component of these concretions (figure). The
tubules were dilated and the tubular epithelium was
flattened. Lymphocytic infiltration was minimal,
and focal fibrosis was seen in less than 10% of the
cortical tissue. Deposits of immunoglobulin or
complement were not seen on immunofluorescence
microscopy.
We made a diagnosis of acute phosphate nephro-
pathy with persistent renal impairment secondary to
the administration of a sodium phosphate purgative.
The patient was discharged on day 22 with predniso-
lone enemas and erythropoietin injections. Serum
creatinine had stabilised at 271 µmol/l (estimated
glomerular filtration rate 15 ml/min/1.73 m2), and
serum phosphate was 1.15 mmol/l.
Discussion
Acute phosphate nephropathy refers to renal impair-
ment caused by diffuse tubular damage as a result of
deposition of calcium phosphate in the distal tubules
and collecting ducts. Interstitial oedema is often
present. Tubular atrophy and interstitial fibrosis
indicate irreversible tubular injury. Unlike nephro-
calcinosis, in which hypercalcaemia promotes an
insidious loss of renal function through chronic
tubulointerstitial injury secondary to the deposition
of calcium crystals in the renal parenchyma,1 2 this
newpathological entity is typically acute in onset and
occurs in the absence of hypercalcaemia.2
Acute phosphate nephropathy is an increasingly
reported cause of chronic kidney disease.1 The rise in
serum creatinine needed for a diagnosis of acute
phosphate nephropathy has varied in studies to date;
a recent study used a ≥50% rise in creatinine from
baseline over 12 months after colonoscopy.1 3
Although the true incidence is therefore unknown,
it may occur in up to 1 in 1000 patients who
receive sodium phosphate and is probably
underdiagnosed.1 2
Oral sodium phosphate preparations promote colo-
nic evacuation by drawing large volumes of water into
the colon (1-1.8 litres of water per 45 ml of
preparation).4 They provoke transient hyperphospha-
taemia (an increase in serum phosphate of 0.165-
0.195 mmol/l),5 which is most profound in elderly
people.6This is rarely associatedwithuntowardevents.
Factors that promote hyperphosphataemia predispose
patients to acute phosphate nephropathy. Such factors
include inappropriate dosing, increased bowel transit
time (for example, bowel obstruction), and reduced
ability to excrete a phosphate load (such as renal
impairment).7
Factors that promote tubular precipitation of cal-
cium phosphate also predispose to acute phosphate
nephropathy. These include inadequate hydration
during phosphate administration, hypertension with
arteriosclerosis, and drugs such as renin-angiotensin
Extensive tubular calcification with little chronic damage as
shown by haematoxylin and eosin stain (top; original
magnification ×200) and von Kossa stain (bottom; original
magnification ×200, courtesy of T Toth)
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inhibitors, diuretics, and non-steroidal anti-inflamma-
tory drugs.2 This first group of drugs limits the kidneys’
capacity to compensate for the reduced renal perfusion
of volumedepletion andaccentuates bicarbonaturia by
inhibiting angiotensin II, thereby enhancing alkalinisa-
tion of the urine and increasing calcium and phosphate
precipitation.8 Heart failure and cirrhosis are further
risk factors,9 10 and the condition seems to be more
prevalent in women.2
Acute phosphate nephropathy may arise in patients
receiving sodium phosphate solutions (Fleet Phospho-
soda; De Witt ) or tablets (Visicol ; Sal ix
Pharmaceuticals).2 11 12 Renal insufficiency is sustained
in most patients, but this varies according to the
increase in creatinine needed for diagnosis.3 In one
study, 19% of patients developed end stage renal
disease,2 whereas in another study only 16% returned
to their baseline renal function.3
Absolute contraindications to oral sodium phos-
phate preparations include renal impairment (phos-
phate excretion is extremely compromised once the
glomerular filtration rate drops to 30 ml/min),6 bowel
obstruction, dehydration, electrolyte disturbances, and
heart failure.8
Our patient had active colitis, a relative contra-
indication to phosphate preparations.7 Older age
(those aged over 57 are at increased risk of acute
phosphate nephropathy) and previous hypertension
are further relative contraindications.6 13
Preventionof acutephosphatenephropathy requires
adequate volume repletion during phosphate
administration.14 Electrolyte rehydration solutions
may help.15 16 Admission for intravenous prehydration
may be necessary. Drugs that alter electrolyte balance
(diuretics) or reduce renal perfusion (renin-angiotensin
inhibitors) should be withheld before phosphate
administration. The appropriate doses should never
be exceeded.
To facilitate evaluation of the risk of acute phosphate
nephropathy, we recommend that the patient’s age,
sex, electrolyte profile, comorbidities (glomerular
filtration rate, hypertension, heart failure), and drugs
are incorporated into the colonoscopy referral form.
Alternative agents that do not provoke such dramatic
osmotic shifts, such as polyethylene glycol solution,
might then be considered in high risk patients—
although sodium phosphate preparations are more
effective and better tolerated.5
We also recommend that clinicians consider
checking serum creatinine about a week after
colonoscopy in high risk patients. Because the
identification at a later date of non-progressive
chronic kidney disease in a typical patient (an elderly
personwith hypertension andminimal proteinuria) is
unlikely to provide a strong indication for renal
biopsy, and because the link between colonoscopy
and renal impairment is less likely to be noticed as
time elapses, failure to check serum creatinine may
lead to cases of acute phosphate nephropathy being
missed. Management strategies will not then be
instituted and the patient may receive further sodium
phosphate preparations.
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10-MINUTE CONSULTATION
Sleep disorder (insomnia)
Bruce Arroll, Antonio Fernando III, Karen Falloon
A 53 year old man comes to you complaining of not
having sleptwell formanyyears.He always feels tired
the next day. He has tried sleeping pills, which
sometimes help, but he is not keen on taking them
continually and has found that the benefits they give
him don’t last. He spends about 9-10 hours in bed
each night (going to bed about 9 30 pm or 10 pm and
getting up at 7 am) and has trouble getting to sleep.
His actual hours of sleep are 5.5 to 6 each night. He
wakes about three times a night and describes the
quality of his sleep as poor.
What issues you should cover
Assessment
Rule out secondary causes. To assess whether he has
depression or anxiety, for example, ask screening
questions, take a full history of depression and anxiety,
or use a scale such as the Hospital Anxiety and
Depression Scale, which gives a score for both condi-
tions. Consider sleep apnoea if he snores a lot at night,
has periods of apnoea, falls asleep easily during the day
(for instance, as a passenger in a car, in lectures, or in
waiting rooms), and is overweight. (Sleep laboratory
assessment may be needed if this diagnosis is not clear.)
Ashis general practitioner youwill knowwhether hehas
severe pain or a breathing condition—these may need
treatment.Delayed sleepphase iswhere people prefer to
go to sleep and wake upmore than two hours later than
societal norms. You can ask directly about parasomnias
(sleep walking, sleep talking, and restless legs syn-
dromes). If hehasnoneof these heprobablyhas primary
insomnia—his insomnia is not due to any other cause
and hence is a diagnosis of exclusion.
Documenting insomnia
Youcould askhim to keepa sleepdiaryover 1-2weeks.
Or ask himwhat time he puts out the lights, howmany
minutes it takes him to get to sleep, howmany times he
wakes up after first falling asleep and how long he stays
awake, andwhathis finalwaking time is and the timehe
gets outof bed.Fromthis informationyoucancalculate
how much time he spends in bed and how much time
asleep,which canbe expressed as the sleep efficiency—
the percentage of time spent in bed during which he is
asleep. He sleeps for about six hours and is in bed for
nine hours, so his sleep efficiency is about 66%.A sleep
efficiency of 80% to 85% is considered optimal. More
than 90% may indicate sleep deprivation, and below
75% is considered tobe a signof poor quality sleep.Ask
howhe feels whenhewakes up and during the day, and
ask him to describe the quality of his sleep.
What you should do
In primary insomnia the behavioural option of sleep
restriction (restricting theamountof timespent inbed just
to the usual sleeping time) has been shown to work, with
or without cognitive behavioural therapy. As he is
sleeping for only 5.5 to 6 hours, advise him to go to bed
much later than he currently is; thus if he gets up at 6 am
he could go to bed at 12 midnight so that he spends less
time in bed.
Somepatients find this regimequite difficult butwithin
about two weeks find themselves sleeping much better
andreport abetterqualityof sleep. If theyachieve this ina
fewweeks they can start increasing the time spent in bed,
restricting itagain if thequalityof sleepdeteriorates.Once
the patient achieves better quality sleep he can choose to
remain on that schedule.
It is common for patientswith primary insomnia to get
a much higher quality of sleep once they begin sleep
restriction. Their usual response to poor sleep is to spend
more time in bed, which is in fact counterproductive.
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Causes of sleep disorder
Common causes
Depression
Anxiety
Sleep apnoea
Pain or a serious breathing condition
Daytime naps, especially if late in day
Evening consumption of coffee, nicotine, or alcohol
Vigorous physical activity close to bedtime
Shift work
Primary insomnia (in reality all those cases that don’t have
a specific cause)
Causes of unknown prevalence in primary care
Delayed sleep phase (“night owls”)
Parasomnia(sleepwalking,sleeptalking,andrestless legs)
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